Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant furmonertinib in EGFR-mutated locally advanced lung adenocarcinoma
ChiCTR2300076712Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of furmonertinib in Non-small cell lung cancer adenocarcinoma (NSCLC) and non-small cell lung cancer (NSCLC), sponsored by Tongji Hospital. Primary endpoint: Objective response rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300076712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076712.